Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2014

Significant Accounting Policies [Line Items]

Schedule of ResponseDX Accounts Receivable

ResponseDX^® accounts receivable consisted of the following:

	December 31,		December 31,
	2013		2014
Net Medicare receivable	$	2,422,611	$	2,814,989
Net Private Payor receivable		4,315,587		6,029,300
		6,738,198		8,844,289
Allowance for doubtful accounts		(2,404,659)		(2,071,706)
	$	4,333,539	$	6,772,583

Schedule of Estimated Useful Lives of Property and Equipment

The Company has determined the estimated useful lives of its property and equipment, as follows:

Laboratory equipment	5 to 7 years
Furniture and equipment	5 to 7 years
Purchased and internally-developed software	3 to 5 years
Leasehold improvements	Shorter of the useful life (5 to 7 years) or the lease term

Schedule of Revenue Sources that Account for Greater than 10 Percent of Total Revenue

Revenue sources that accounted for greater than 10 percent of revenue are provided below (* indicates amount is below 10%):

	Year Ended December 31,
	2013					2014
			Percent of					Percent of
			Total					Total
	Revenue		Revenue			Revenue		Revenue
GlaxoSmithKline entities:
GlaxoSmithKline LLC	$	1,134,366		5.8	%	$	174,597		*	%
GlaxoSmithKline Biologicals S.A.	$	3,534,619		17.9	%	$	1,287,184		*	%
Total GlaxoSmithKline entities	$	4,668,985		23.7	%	$	1,461,781		*	%
Medicare, net of contractual allowances	$	4,521,732		22.8	%	$	4,886,507		29.2	%

Sales Revenue, Net [Member]

Significant Accounting Policies [Line Items]

Schedule of Revenue by Major Customers by Reporting Segments

The following details ResponseDX^® revenue for the years ended December 31, 2013 and 2014:

	Year Ended December 31,
	2013		2014
Net Medicare revenue	$	4,521,732	$	4,886,507
Net Private Payor revenue		7,489,642		9,709,690
Net ResponseDX® revenue	$	12,011,374	$	14,596,197

Accounts Receivable [Member]

Significant Accounting Policies [Line Items]

Schedule of Revenue by Major Customers by Reporting Segments

Clients that accounted for greater than 10 percent of gross accounts receivable are provided below (* indicates amount is below 10%):

	As of December 31,
	2013					2014
			Percent of					Percent of
	Receivable		Gross			Receivable		Gross
	Balance		Receivables			Balance		Receivables
GlaxoSmithKline entities:
GlaxoSmithKline LLC	$	597,937		6.9	%	$	174,547		*	%
GlaxoSmithKline Biologicals S.A.	$	544,298		6.3	%	$	588,212		*	%
Total GlaxoSmithKline entities	$	1,142,235		13.2	%	$	762,759		*	%
Medicare, net of contractual allowances	$	2,422,611		28.1	%	$	2,814,989		28.5	%